JAZZ changes
Pick any two versions below to diff them.
- Price
- $230.26
- Discount category
- Close to intrinsic value
- Next earnings
- Feb 23, 2027
- Next earnings is estimate
- Yes
- Company name
- added: Jazz Pharmaceuticals
- Sector
- added: Biopharmaceuticals: sleep, epilepsy and oncology medicines
- About
- added: Jazz Pharmaceuticals plc (Jazz) is based in Dublin, Ireland. It develops and sells medicines for sleep disorders, epilepsy and cancer. Its largest product is Xywav, a low-sodium oxybate for narcolepsy and idiopathic hypersomnia (IH). It also sells Epidiolex/Epidyolex for seizures in rare epilepsies, and the oncology medicines Zepzelca, Rylaze/Enrylaze, Defitelio, Modeyso, Vyxeos and Ziihera. Total revenues were $1,243.0 million in Q3 2026 and $3,520.2 million for nine months. In Q3 2026, Xywav made $482.8 million, Epidiolex/Epidyolex $295.4 million and oncology $387.1 million. The ordinary shares trade on Nasdaq in US dollars. Jazz files 10-K and 10-Q reports.
- Thesis
- added: The price of Jazz depends on how much of its Xywav revenue stays after its orphan drug exclusivity ends, and on whether its newer medicines can replace it. FDA orphan drug exclusivity for Xywav runs to January 2028 in narcolepsy and to August 2028 in IH. Lupin, Teva and Granules filed for generic versions of Xywav, and the patent case against Lupin and Teva has no trial date. Takeda's Orzeyful, the first approved oral orexin 2 receptor agonist, will compete in narcolepsy type 1 when it launches. Generic high-sodium oxybate already lowers Xyrem sales and royalty revenues. Jazz also carries $5.6 billion of debt principal, and it spent $820.0 million on Actio in September 2026. For the price to rise, four things must be true. Xywav must keep adding patients and keep its sales after 2028. Ziihera must grow in first-line HER2-positive gastroesophageal adenocarcinoma, which the FDA approved in August 2026. Modeyso and the new Epidiolex capsule must pass their next tests. Cash flow must lower the debt. The Q4 2026 report in February 2027, the FDA decision on the Epidiolex capsule on April 16, 2027 and the Modeyso survival analysis in the first half of 2027 are the next tests.
- Risks
- added: Revenue depends on Xywav, which faces generic and branded competition. Orphan drug exclusivity ends in January 2028 for narcolepsy and in August 2028 for IH. Lupin, Teva and Granules filed abbreviated new drug applications for generic Xywav, and Tris Pharma filed a Section 505(b)(2) application that names Xyrem and Xywav. New narcolepsy medicines can take patients. The 10-Q names Alkermes' Lumryz, Takeda's Orzeyful and orexin 2 receptor agonists that Merck, Eisai, Eli Lilly and Alkermes develop. Debt is high. Debt principal was $5.6 billion at September 30, 2026. The 2030 exchangeable notes of $1.0 billion are exchangeable now, and Jazz must pay their principal in cash. New medicines must pass clinical and regulatory tests. The Modeyso ACTION trial, the Epidiolex capsule application and the ABS-1230 study can fail or take longer, and Jazz recorded acquired research costs of $831.2 million in nine months of 2026. Generic Epidiolex can come later. Jazz settled with ten generic filers, which can sell generic Epidiolex in the US from the very late 2030s, or earlier in some conditions.
- Balance sheet
- added: Cash: $2.9B Debt: $5.6B Net debt: $2.7B Undrawn credit line: $885M, to November 2029 Last debt due: 2033 At September 30, 2026, Jazz had cash and cash equivalents of $2,036.4 million and investments of $820.0 million, which is $2,856.4 million in all. Debt principal was $5.6 billion: about $1.9 billion of Tranche B-3 term loans due May 5, 2033, $1.5 billion of 4.375% senior secured notes due 2029, $1.25 billion of 1.875% exchangeable notes due 2032 and $1.0 billion of 3.125% exchangeable notes due 2030. The 2030 notes are in current liabilities because the share price condition for exchange was met, but their maturity is 2030. The revolving credit facility of $885.0 million was undrawn and matures on November 26, 2029. Operating cash flow was $1,330.0 million for nine months. Shareholders' equity was $4,191.8 million. As of Sep 30, 2026.
- Checkpoints
- added: Feb 23, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: Total revenues for 2026 are in the raised range of $4,775 million to $4,850 million and the 2027 guidance shows growth, and this passes; revenues below the range or lower guidance for 2027 fail. Apr 16, 2027: FDA decision on the Epidiolex capsule. Pending. Watch: The FDA approves the oral cannabidiol capsule by its target action date of April 16, 2027, and this passes; a rejection or a delay fails. Q2 2027 (estimate): Modeyso ACTION survival analysis. Pending. Watch: The interim overall survival analysis of the Phase 3 ACTION trial, expected in the first half of 2027, shows a benefit for Modeyso, and this passes; no benefit or a delay past mid-2027 fails.
- Recent events
- added: Nov 2, 2026: Jazz reported Q3 2026 results. Total revenues rose 10% to $1,243.0 million. The GAAP net loss was $483.4 million, because of an acquired in-process research and development expense of $754.2 million for ABS-1230 (JZP6979) from Actio. Jazz raised its 2026 total revenue guidance to $4,775 million to $4,850 million, from $4,600 million to $4,750 million. In October 2026, the board approved a new share repurchase program of up to $500 million. Oct 6, 2026: Samantha Pearce, Executive Vice President and Chief Commercial Officer, told Jazz that she will retire when a successor is appointed, or by June 30, 2027 at the latest. Sep 23, 2026: Jazz amended its term loan B. The interest margin fell by 0.50 percentage points and the maturity moved to May 2033. Sep 15, 2026: Jazz completed the acquisition of Actio Biosciences for an upfront payment of $820.0 million, net of cash acquired. It can pay up to $500.0 million more when regulatory and commercial milestones occur. The deal adds ABS-1230 (JZP6979), a treatment candidate for KCNT1-related epilepsy. Aug 26, 2026: Jazz sold $1.25 billion of 1.875% exchangeable senior notes due 2032 in a private placement. At the same time, it repurchased $225 million of its ordinary shares. Aug 25, 2026: The FDA approved Ziihera for the first-line treatment of adults with HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma. Jun 15, 2026: Jazz repaid $1.0 billion of exchangeable notes at maturity in cash and issued 1,890,193 ordinary shares for the conversion premium.